Clinical Trial Update: Study of ADI-PEG 20 Versus Placebo in Subjects With NASH [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating ADI-PEG 20 versus placebo in adults with nonalcoholic steatohepatitis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis

Drugs mentioned

• ADI-PEG 20 (pegylated arginine deiminase)

Snippet

Sponsor: Polaris Group | Conditions: Nonalcoholic Steatohepatitis (NASH) | Phase 2 | Status: RECRUITING